Price T Rowe Associates Inc. MD cut its stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 33.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,394,306 shares of the company's stock after selling 690,381 shares during the quarter. Price T Rowe Associates Inc. MD owned about 2.44% of Structure Therapeutics worth $37,814,000 at the end of the most recent quarter.
Several other large investors have also recently made changes to their positions in the stock. Geode Capital Management LLC boosted its holdings in shares of Structure Therapeutics by 0.7% in the 3rd quarter. Geode Capital Management LLC now owns 45,225 shares of the company's stock valued at $1,985,000 after buying an additional 312 shares in the last quarter. ANTIPODES PARTNERS Ltd increased its position in shares of Structure Therapeutics by 115.0% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock worth $28,000 after purchasing an additional 553 shares in the last quarter. LPL Financial LLC lifted its holdings in shares of Structure Therapeutics by 6.0% during the 4th quarter. LPL Financial LLC now owns 11,485 shares of the company's stock valued at $311,000 after purchasing an additional 646 shares during the last quarter. Envestnet Asset Management Inc. grew its stake in Structure Therapeutics by 12.9% during the 4th quarter. Envestnet Asset Management Inc. now owns 7,403 shares of the company's stock worth $201,000 after buying an additional 843 shares during the last quarter. Finally, Money Concepts Capital Corp boosted its stake in Structure Therapeutics by 4.2% in the 4th quarter. Money Concepts Capital Corp now owns 21,031 shares of the company's stock worth $570,000 after purchasing an additional 848 shares in the last quarter. 91.78% of the stock is owned by institutional investors.
Analysts Set New Price Targets
A number of research analysts have issued reports on the stock. Citigroup started coverage on shares of Structure Therapeutics in a report on Friday. They issued a "buy" rating and a $60.00 price target for the company. Stifel Nicolaus initiated coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They set a "buy" rating and a $50.00 price target on the stock. HC Wainwright restated a "buy" rating and issued a $80.00 price objective on shares of Structure Therapeutics in a research note on Tuesday, April 22nd. Finally, William Blair initiated coverage on Structure Therapeutics in a research report on Friday, February 28th. They issued an "outperform" rating on the stock. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $78.63.
Get Our Latest Analysis on Structure Therapeutics
Structure Therapeutics Price Performance
NASDAQ:GPCR traded down $0.41 during trading hours on Monday, reaching $26.68. The company had a trading volume of 100,049 shares, compared to its average volume of 919,723. The firm has a market cap of $1.53 billion, a PE ratio of -36.26 and a beta of -1.35. Structure Therapeutics Inc. has a 1-year low of $13.22 and a 1-year high of $62.74. The business's 50 day moving average price is $20.52 and its 200-day moving average price is $27.30.
Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.01. On average, analysts expect that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.
Structure Therapeutics Company Profile
(
Free Report)
Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
Featured Articles
Before you consider Structure Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.
While Structure Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
